13F filings

Deep Track Capital

Its 13F for Q2 2026, filed Aug 14, 2026.

The filing on EDGAR

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

Biggest moves

Q2 2026, quarter ended Jun 30

Deep Track opened $248.3M of Alnylam Pharmaceuticals in Q2 2026.

A new position, 3.6% of the 13F value at Jun 30.

XBI State Street SPDR S&P Biotech ETF, put−$1.3B
MANE Veradermics+$184.4M
APLS Apellis Pharmaceuticals, sold out−$182.3M
COAG Hemab Therapeutics Holdings, new+$132.3M
CNTA Centessa Pharmaceuticals, sold out−$125.4M
AXSM Axsome Therapeutics−$97.9M
GHRS GH Research, new+$89.6M
IMVT Immunovant−$84.2M

Calls and puts in grey: an option is not a buy or a sale of the stock, and its amount is as filed, mostly the value of the shares underneath. Every filed line is in the list below.

13F value

Held on Jun 30, 2026
$6.9B

in 67 positions.

Sector mix by disclosed value

  • Healthcare98.8%
  • Options and unclassified (not a sector)1.2%

The grey slice is mostly calls and puts (1.2% of the disclosed value), which get no sector because a put is a position against a company.

Q1 2026 filing$6.1B
Q2 2026 filing$6.9B

+12.2% filing to filing, from price moves and buying or selling: not the fund’s return. Not investment advice.

GetSignal estimate

Two figures, two sources

Assets under management, as reported to the SEC

$8.4B

Regulatory assets under management on Form ADV, filed Mar 31, 2026 by Deep Track Capital, LP. A gross figure: it counts borrowed money and assets a 13F never lists, so it is not the 13F value.

13F stock positions at the latest close

$5.9B

−13.5% on the $6.8B of stock lines filed for Jun 30

If unchanged since Jun 30, 2026: the filing's stock lines at the Nov 12 close. Options and bonds left out; 95.6% of the value priced, the rest carried at its filed value. An estimate of what the filed positions are worth now, not a forecast and not the fund's return. How it is made. Not investment advice.

New positions

Q2 2026 13F, calls and puts aside
5

new positions among the 15 largest moves. Worth $603.9M together at Jun 30.

COAGHemab Therapeutics Holdings$132.3M
GHRSGH Research$89.6M
AVTXAvalo Therapeutics$66.7M

Sold out

Q2 2026 13F, calls and puts aside
3

positions sold out among the 15 largest moves. Worth $370.3M together at Mar 31, the quarter before.

APLSApellis Pharmaceuticals$182.3M
CNTACentessa Pharmaceuticals$125.4M

Largest holdings

50 largest of 67 positions

Guardant Health is the largest, at 7.4% of the 13F value. The five largest are 23.6%.

HoldingTypeValueShares% of 13F value
GHGuardant HealthShares$509.1M3,393,312 shares7.4%
IMVTImmunovantShares$359.9M9,341,151 shares5.2%
GPCRStructure TherapeuticsShares$254.4M4,740,072 shares3.7%
PCVXVaxcyteShares$250.0M4,300,000 shares3.6%
ALNYAlnylam PharmaceuticalsShares$248.3M825,000 shares3.6%
MANEVeradermicsShares$245.9M2,000,000 shares3.6%
TARSTarsus PharmaceuticalsShares$230.8M3,666,768 shares3.4%
NUVLNuvalentShares$220.2M1,783,322 shares3.2%
ALKSAlkermesShares$209.6M4,000,000 shares3.1%
OCULOcular TherapeutixShares$193.3M19,686,282 shares2.8%
BMRNBioMarin PharmaceuticalShares$189.3M3,307,481 shares2.8%
NRIXNurix TherapeuticsShares$187.7M7,736,455 shares2.7%
ORKAOruka TherapeuticsShares$183.3M1,926,000 shares2.7%
ALMSAlumisShares$178.6M6,348,558 shares2.6%
IONSIonis PharmaceuticalsShares$174.4M2,200,000 shares2.5%
CMPSCOMPASS PathwaysShares$172.1M12,161,496 shares2.5%
VERAVera TherapeuticsShares$171.6M4,000,000 shares2.5%
AXSMAxsome TherapeuticsShares$171.3M700,000 shares2.5%
GMABGenmab A/SShares$155.2M5,650,000 shares2.3%
MLTXMoonLake ImmunotherapeuticsShares$136.3M6,999,025 shares2.0%
COAGHemab Therapeutics HoldingsShares$132.3M3,602,093 shares1.9%
TNGXTango TherapeuticsShares$131.3M4,200,000 shares1.9%
DFTXDefinium TherapeuticsShares$129.4M2,750,000 shares1.9%
GRALGRAILShares$125.3M1,834,944 shares1.8%
BCAXBicara TherapeuticsShares$121.7M4,100,000 shares1.8%
MAZEMaze TherapeuticsShares$111.4M3,732,569 shares1.6%
CLDXCelldex TherapeuticsShares$109.4M2,939,151 shares1.6%
LBRXLB PharmaceuticalsShares$108.8M3,352,804 shares1.6%
MBXMBX BiosciencesShares$95.6M1,732,569 shares1.4%
GHRSGH ResearchShares$89.6M3,333,334 shares1.3%
GMABGenmab A/SCall$82.4M3,000,000 shares1.2%
COGTCogent BiosciencesShares$77.4M2,000,000 shares1.1%
ATAIAtaibeckleyShares$76.0M14,417,442 shares1.1%
UTHRUnited TherapeuticsShares$67.0M123,616 shares1.0%
AVTXAvalo TherapeuticsShares$66.7M3,610,000 shares1.0%
VRDNViridian TherapeuticsShares$66.0M3,592,740 shares1.0%
CYTKCytokineticsShares$59.6M700,000 shares0.9%
ALTAltimmuneShares$58.5M19,250,000 shares0.9%
PSNLPersonalisShares$53.6M4,000,000 shares0.8%
ACRSAclaris TherapeuticsShares$49.4M9,345,000 shares0.7%
CRMDCorMedixShares$49.3M6,274,076 shares0.7%
WGSGeneDx HoldingsShares$48.1M700,000 shares0.7%
HROWHarrow HealthShares$41.2M969,000 shares0.6%
CRVSCorvus PharmaceuticalsShares$37.2M2,491,939 shares0.5%
SLDBSolid BiosciencesShares$35.6M3,565,062 shares0.5%
BEAMBeam TherapeuticsShares$34.3M1,000,000 shares0.5%
DYNDyne TherapeuticsShares$33.3M1,500,000 shares0.5%
IMMXImmix BiopharmaShares$28.6M2,775,000 shares0.4%
XFORX4 PharmaceuticalsShares$27.5M5,878,757 shares0.4%
STTKShattuck LabsShares$25.7M3,706,734 shares0.4%

% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed. Calls and puts are shown as filed: most filers give Value as the notional value of the shares underneath, not money invested, but some give the premium paid, and some count contracts rather than shares.

13F moves15 largest moves, line by line

What Deep Track Capital bought and sold in Q2 2026

Each filed line against the Q1 2026 filing.
HoldingMoveShare changeEst. amount movedValue after
XBIState Street SPDR S&P Biotech ETFExited put-100%-$1.3B$0 after
ALNYAlnylam PharmaceuticalsNewnew+$248.3M$248.3M after
MANEVeradermicsAdded+300.0%+$184.4M$245.9M after
APLSApellis PharmaceuticalsExited-100%-$182.3M$0 after
COAGHemab Therapeutics HoldingsNewnew+$132.3M$132.3M after
CNTACentessa PharmaceuticalsExited-100%-$125.4M$0 after
BMRNBioMarin PharmaceuticalAdded+187.6%+$123.5M$189.3M after
AXSMAxsome TherapeuticsTrimmed-36.4%-$97.9M$171.3M after
GHRSGH ResearchNewnew+$89.6M$89.6M after
IMVTImmunovantTrimmed-19.0%-$84.2M$359.9M after
GMABGenmab A/SNew callnew+$82.4M$82.4M after
UTHRUnited TherapeuticsNewnew+$67.0M$67.0M after
AVTXAvalo TherapeuticsNewnew+$66.7M$66.7M after
BBIOBridgeBio PharmaExited-100%-$62.5M$0 after
CLDXCelldex TherapeuticsAdded+128.9%+$61.6M$109.4M after

A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end. A put gains when the stock falls; a call gains when it rises. Option values are as filed, which for most filers is the notional value of the shares underneath.

Source: Form 13F, filed with the SEC on Aug 14, 2026, for positions held on Jun 30, 2026. A 13F lists US-listed stock and options at their quarter-end value; short sales, cash and most bonds are not in it. Methodology · Guide to Form 13F. Checked for newer filings on Nov 14, 2026. Not investment advice.

Questions

What Deep Track Capital holds, what moved and how current the filing is.

What does Deep Track Capital hold?

Deep Track Capital disclosed 67 positions worth $6.9B in the Q2 2026 13F filing. The largest is GH at 7.4% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.

What did Deep Track Capital buy and sell last quarter?

Comparing the Q2 2026 filing with the quarter before, the largest moves were selling out of a put on XBI, opening a position in ALNY, adding to MANE and selling out of APLS. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.

How current is this?

This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.

Other managers we track

ranked by stock held
See every manager we track